Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
A Clinical Assessment of Combination Therapy With Differin® Gel, 0.3% With Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95819
- Center for Dermatology and Laser Surgery
-
-
Kentucky
-
Louisville, Kentucky, United States, 40217
- Derm Research, P.L.L.C.
-
-
Ohio
-
Warren, Ohio, United States, 44483
- Brodell Medical
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Northwest Cutaneous Research Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with a minimum of 20 inflammatory lesions on the face;
- Subjects with a minimum of 15 and a maximum of 100 non-inflammatory lesions (open and closed comedones) on the face, excluding the nose;
- Subject has a Global Severity Assessment
Exclusion Criteria:
1. Subjects with more than three nodulo-cystic lesions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Study Treatment
adapalene gel, 0.3% Other Names: Differin® Gel, 0.3% Applied once daily at bedtime clindamycin/benzoyl peroxide gel Other Names: Duac® Gel Applied once daily in the morning |
Applied once daily at bedtime
Other Names:
Applied once daily in the morning
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change From Baseline in Total Lesion Counts
Time Frame: 6 and 12 weeks
|
6 and 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Severity Assessment Success
Time Frame: 6 and 12 weeks
|
Global Severity was assessed on a 6 point scale (Clear, Almost Clear, Mild, Moderate, Severe).
The scale was dichotomized to success or failure where success = Clear or Almost Clear
|
6 and 12 weeks
|
|
Global Assessment of Improvement From Baseline
Time Frame: 12 weeks
|
12 weeks
|
|
|
Worst Post Baseline Tolerability Assessment - Erythema
Time Frame: 12 weeks
|
Please Note: "Tolerability Assessments" were captured separately from adverse events.
Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
|
12 weeks
|
|
Worst Post Baseline Tolerability Assessment - Scaling
Time Frame: 12 weeks
|
Please Note: "Tolerability Assessments" were captured separately from adverse events.
Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
|
12 weeks
|
|
Worst Post Baseline Tolerability Assessment - Dryness
Time Frame: 12 weeks
|
Please Note: "Tolerability Assessments" were captured separately from adverse events.
Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
|
12 weeks
|
|
Worst Post Baseline Tolerability Assessment - Burning/Stinging
Time Frame: 12 weeks
|
Please Note: "Tolerability Assessments" were captured separately from adverse events.
Tolerability changes that required a dose modification or concomitant treatment were to be recorded on the Adverse Event CRF.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ron W Gottschalk, MD, Galderma R&D
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Acneiform Eruptions
- Sebaceous Gland Diseases
- Acne Vulgaris
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Dermatologic Agents
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
- Benzoyl Peroxide
- Adapalene
Other Study ID Numbers
Other Study ID Numbers
- US10066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.